CAMP4 Therapeutics Corp
CAMP2.280USD
-0.220-8.80%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
45.97MMarket Cap
LossP/E TTM
More Details of CAMP4 Therapeutics Corp Company
CAMP4 Therapeutics Corporation is a clinical-stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics with the goal of upregulating gene expression and restoring healthy protein levels to treat a broad range of genetic diseases. It is leveraging its RAP Platform to advance a pipeline of programs initially focused on metabolic and central nervous system (CNS) disorders with validated disease biology and potential market opportunities due to the significant unmet need of affected patients. Its lead product candidate, CMP-CPS-001, has the potential to be the first disease-modifying therapy for the treatment of urea cycle disorders. CMP-CPS-001 is designed to improve urea cycle activity by amplifying expression of CPS1, a key enzyme that catalyzes the first step of the urea cycle, by binding to a CPS1-specific regRNA. Its CNS development program, CMP-SYNGAP, is focused on addressing the underlying cause of SYNGAP1-related disorders.
Company Info
Ticker SymbolCAMP
Company nameCAMP4 Therapeutics Corp
IPO dateOct 11, 2024
CEOMr. Josh Mandel-Brehm
Number of employees55
Security typeOrdinary Share
Fiscal year-endOct 11
AddressOne Kendall Square
CityCAMBRIDGE
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code02139
Phone16176518867
Websitehttps://www.camp4tx.com/
Ticker SymbolCAMP
IPO dateOct 11, 2024
CEOMr. Josh Mandel-Brehm
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Josh Mandel-Brehm
Mr. Josh Mandel-Brehm
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
278.42K
+2.23%
Dr. Richard A. (Rick) Young, Ph.D.
Dr. Richard A. (Rick) Young, Ph.D.
Independent Director
Independent Director
170.01K
+9.78%
Mr. Steven H. (Steve) Holtzman, Ph.D.
Mr. Steven H. (Steve) Holtzman, Ph.D.
Independent Director
Independent Director
108.95K
--
Ms. Kelly Gold
Ms. Kelly Gold
Chief Financial Officer
Chief Financial Officer
67.88K
+9.80%
Mr. Michael J. Higgins
Mr. Michael J. Higgins
Independent Director
Independent Director
28.74K
--
Dr. Douglas E. (Doug) Williams, Ph.D.
Dr. Douglas E. (Doug) Williams, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
2.50K
--
Dr. Murray W. Stewart, M.D.
Dr. Murray W. Stewart, M.D.
Independent Director
Independent Director
--
--
Dr. Yuri Maricich, M.D.
Dr. Yuri Maricich, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Amir H. Nashat
Dr. Amir H. Nashat
Independent Director
Independent Director
--
--
Mr. David Bumcrot, Ph.D.
Mr. David Bumcrot, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Josh Mandel-Brehm
Mr. Josh Mandel-Brehm
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
278.42K
+2.23%
Dr. Richard A. (Rick) Young, Ph.D.
Dr. Richard A. (Rick) Young, Ph.D.
Independent Director
Independent Director
170.01K
+9.78%
Mr. Steven H. (Steve) Holtzman, Ph.D.
Mr. Steven H. (Steve) Holtzman, Ph.D.
Independent Director
Independent Director
108.95K
--
Ms. Kelly Gold
Ms. Kelly Gold
Chief Financial Officer
Chief Financial Officer
67.88K
+9.80%
Mr. Michael J. Higgins
Mr. Michael J. Higgins
Independent Director
Independent Director
28.74K
--
Dr. Douglas E. (Doug) Williams, Ph.D.
Dr. Douglas E. (Doug) Williams, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
2.50K
--
Revenue Breakdown
FY2025Q1
No Data
By RegionUSD
Name
Revenue
Proportion
United States
858.00K
0.00%
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, Sep 19
Updated: Fri, Sep 19
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
5AM Ventures
43.70%
Polaris Partners
19.50%
Vivo Capital, LLC
19.45%
Enavate Sciences GP, LLC
18.78%
Northpond Ventures, LLC
11.10%
Shareholders
Shareholders
Proportion
5AM Ventures
43.70%
Polaris Partners
19.50%
Vivo Capital, LLC
19.45%
Enavate Sciences GP, LLC
18.78%
Northpond Ventures, LLC
11.10%
Shareholder Types
Shareholders
Proportion
Venture Capital
84.79%
Corporation
38.28%
Private Equity
6.31%
Investment Advisor
5.26%
Individual Investor
3.47%
Investment Advisor/Hedge Fund
2.06%
Hedge Fund
1.82%
Research Firm
0.15%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
73
18.38M
91.17%
+4.63M
2025Q1
74
18.54M
91.98%
+4.88M
2024Q4
55
18.62M
92.36%
+8.29M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
5AM Ventures
2.93M
14.52%
--
--
Mar 31, 2025
Polaris Partners
2.63M
13.02%
+2.63M
--
Oct 15, 2024
Enavate Sciences GP, LLC
3.79M
18.78%
--
--
Mar 31, 2025
Northpond Ventures, LLC
2.24M
11.1%
+2.24M
--
Oct 22, 2024
Andreessen Horowitz
2.13M
10.54%
--
--
Mar 31, 2025
HarbourVest Partners, L.L.C.
1.27M
6.31%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
766.95K
3.8%
+11.92K
+1.58%
Mar 31, 2025
The Vanguard Group, Inc.
233.83K
1.16%
+45.92K
+24.43%
Mar 31, 2025
Mandel-Brehm (Josh)
272.36K
1.35%
-605.00
-0.22%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Sep 6
Updated: Sat, Sep 6
Name
Proportion
Proshares Ultra Russell 2000
0%
iShares Russell 2000 ETF
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 Value ETF
0%
iShares Micro-Cap ETF
0%
Global X Russell 2000 ETF
0%
ProShares UltraPro Russell2000
0%
iShares Russell 2000 Growth ETF
0%
Proshares Ultra Russell 2000
Proportion0%
iShares Russell 2000 ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
iShares Micro-Cap ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
